Instability of p53 in renal cell carcinoma (RCC) has not been previously associated with mutations, because 96% of clear-cell RCC samples in the database were present with the p53 wild type.^[@bib1]^ However, inhibition of a major p53 regulator in humans doubles minute 2 homolog (HDM2) induced cell cycle arrest but not cell death in RCC.^[@bib2]^ Therefore, overcoming p53 instability is a major issue in RCC treatment.

Recently, our group^[@bib3]^ and others^[@bib4]^ have found that the expression level of transglutaminase 2 (TGase 2, E.C. 2.1.2.13) is generally elevated in most RCC cell lines, which deplete p53 into aggregates in the autophagosome, resulting in p53 depletion through autophagy.^[@bib3]^ This p53 instability by TGase 2 regulation allows tumor cells to evade apoptosis and grow remarkably.

TGase 2 is an enzyme that catalyzes an isopeptide bond between protein glutamine and lysine residues, resulting in a covalent cross-link.^[@bib5]^ In normal physiological conditions, TGase 2 contributes toward regulating apoptosis from intruders or damages, including biological, chemical and physical challenges.^[@bib6]^ However, TGase 2 knockout mice display impaired autophagy under starvation,^[@bib7]^ although TGase 2 knockout mice present with an otherwise normal life.^[@bib8],\ [@bib9]^ Cancer cells adopt TGase 2 mediated autophagy for survival.

TGase 2 competes with HDM2 for binding to p53; promotes autophagy-dependent p53 degradation in RCC cell lines under starvation; and binds to p53 and p62 simultaneously without ubiquitin-dependent recognition of p62. The bound complex does not have cross-linking activity. A binding assay using a series of deletion mutants of p62, p53 and TGase 2 revealed that the PB1 domain of p62 (residues 85--110) directly interacts with the β-barrel domains of TGase 2 (residues 592--687), whereas the HDM2-binding domain (transactivation domain, residues 15--26) of p53 interacts with the N-terminus of TGase 2 (residues 1--139).^[@bib1]^ During translocation of p53 to the autophagosome through TGase 2 binding, cross-linking activity is not needed. This finding is in agreement with the observation that TGase 2 cross-linking activity occurs only in the autophagosome during autophagy.^[@bib1],\ [@bib7]^ This suggests that TGase 2 acts as a chaperone of p53 with a cross-linking catalytic activity. This interaction may result in rapid autophagy without consuming energy to tag ubiquitin on p53, as p62 is known to interact with ubiquitinated proteins (see [Figure 1](#fig1){ref-type="fig"}). This autophagy process is beneficial in which it supplies building blocks, including degraded p53, for cancer cells.

We recently reported that monotherapy using the TGase 2 inhibitor GK921 in a xenograft tumor model abrogated RCC growth through p53 stabilization.^[@bib10]^ In addition to the increase in p53 stability due to TGase 2 inhibition, the administration of a DNA-damaging anti-cancer drug such as doxorubicin, remarkably induced apoptosis in RCC cell lines and sensitively reduced tumor volume in a xenograft model. Combination therapy with a TGase 2 inhibitor and a DNA-damaging agent may represent an effective therapeutic approach for treating RCC.
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![(1) In normal cell, p53 stability depends more on HDM2 regulation due to no induction of TGase 2. (2) In cancer cell, TGase 2 is induced by stress such as hypoxia or starvation. The N-terminus of TGase 2 interacts with the N-terminus of p53 and, simultaneously, the C-terminus of TGase 2 interacts with the N-terminus of p62; as a result, a heterotrimeric complex (p53--TGase 2--p62) is formed. The C-terminus of p62, in the p53--TGase 2--p62 complex, is free and moves the complex to LC3 in the phagophore. When the autophagosome is completed with components of the phagophore, p53 is polymerized by TGase 2 with calcium-dependent activation in the autophagosome. Later, the autophagosome and lysosome are fused into an autolysosome, which degrades all cross-linked materials](cddis201699f1){#fig1}
